DEFA14A: ESSA Pharma Sets $80M Distribution Ex-Dividend Date

ESSA Pharma Inc. announced the ex-dividend date and due bill trading procedures for its US$80 million return of capital distribution as part of its winding-up and acquisition by XenoTherapeutics.

Summary

• ESSA Pharma Inc. is proceeding with a return of capital distribution totaling US$80,000,000 to its common shareholders.
• This distribution is part of the discontinuance and winding-up of the company's business, following its previously announced acquisition by XenoTherapeutics, Inc., a non-profit biotechnology company.
• Shareholders are scheduled to receive approximately $1.69 per common share in the distribution, subject to applicable withholding.
• The payment date for the distribution is August 22, 2025.
• Nasdaq has determined the ex-dividend date for the distribution will be August 25, 2025, the first business day after the payment date.
• Due to the distribution representing more than 25% of the common shares' price, Nasdaq has mandated due bill trading from August 19, 2025, through August 25, 2025.
• During the Due Bill Period, shareholders selling common shares will also be selling their right to the distribution, while purchasers will be entitled to receive it.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing details the procedural aspects of a previously announced corporate action (winding-up and acquisition) and a planned return of capital to shareholders. It is neither a positive operational development nor an unexpected negative event, but rather the execution of a strategic decision.

Positives

• Shareholders will receive a significant cash distribution of approximately $1.69 per common share, totaling US$80,000,000, as part of the return of capital.

Negatives

• The company is discontinuing and winding-up its business, indicating the cessation of its independent operations and development of novel therapies for prostate cancer.

Risks

• The completion of the distribution and the transaction with XenoTherapeutics on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and satisfaction of other conditions.
• Potential for the date of the Special Meeting to change.
• Potential litigation relating to the transaction that could be instituted by or against the company, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Risk that disruptions from the transaction will harm the company's business, including current plans and operations.
• Ability to retain and hire key personnel during the transition.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting the company's business.
• Accuracy of the company's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the transaction that may impact the company's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the transaction.
• Possibility that the transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the transaction.

Future Outlook

The future outlook is centered on the completion of the previously announced transaction with XenoTherapeutics, Inc., which involves the acquisition of all issued and outstanding common shares and the discontinuance and winding-up of ESSA Pharma's business. The company anticipates the distribution of US$80,000,000 to shareholders on August 22, 2025, with the ex-dividend date set for August 25, 2025.

Management Comments

• The company issued a press release announcing the ex-dividend date and Nasdaq due bill trading procedures for the previously announced cash distribution.

Industry Context

This announcement signifies ESSA Pharma's exit as an independent entity from the pharmaceutical industry, specifically its focus on developing therapies for prostate cancer. The acquisition by XenoTherapeutics, a non-profit biotechnology company, and the subsequent winding-up of ESSA's business, represents a specific corporate action rather than a reflection of broader industry trends in drug development or market performance.

Comparison to Industry Standards

• This filing details a specific corporate action (return of capital, winding-up, acquisition) rather than operational or financial performance that can be directly benchmarked against industry standards or comparable companies. The distribution of capital is a consequence of the strategic decision to cease operations and be acquired, not a measure of competitive standing or operational efficiency within the prostate cancer therapy market.

Legal Proceedings

• Potential litigation relating to the transaction could be instituted by or against the company, XenoTherapeutics, XOMA Royalty Corporation, or their respective directors or officers.

Stakeholder Impact

• Shareholders: Will receive a cash distribution of approximately $1.69 per common share, but the company's independent operations will cease.
• Employees: The winding-up of the business likely implies job discontinuations or transfers, though not explicitly detailed.
• Customers/Suppliers: The discontinuance of the company's business will impact existing relationships and contracts.

Next Steps

• Payment of the US$80,000,000 distribution to shareholders on August 22, 2025.
• Trading of common shares with due bills until the ex-dividend date of August 25, 2025.
• Settlement of due bill obligations between brokers representing buyers and sellers of common shares.
• Completion of the transaction with XenoTherapeutics, Inc. and the winding-up of ESSA Pharma's business.

Key Dates

Keywords

ESSA Pharma, XenoTherapeutics, Return of Capital, Cash Distribution, Ex-Dividend Date, Due Bill Trading, Acquisition, Winding-up, Corporate Action, Nasdaq, EPIX